银屑病关节炎当前处方实践与共享决策的国际多中心分析
ASSIST横断面观察研究纳入英国、法国、德国、意大利和西班牙24个中心的503例银屑病关节炎患者,记录2021年7月至2022年3月面对面就诊时的治疗决策,以CollaboRATE量表评估临床医生协作努力、PEPPI-5评估患者沟通信心。结果显示英国传统合成改善病情抗风湿药使用比例高于欧洲大陆(66.4% vs 44.9%),生物制剂比例较低(36.4% vs 64.4%),治疗升级在英国最常见,各中心协作评分均较高。
要点
- 英国传统合成DMARDs占当前治疗比例高于欧洲大陆(66.4% vs 44.9%),生物制剂比例较低(36.4% vs 64.4%)。
- CollaboRATE与PEPPI-5评分在各中心均较高,提示面对面咨询中共享决策实施有效。
- 31例CollaboRATE低分(<4.5)患者中,PsAID-12低分(<5)者无治疗升级;465例CollaboRATE≥4.5者中59例PsAID-12低分者接受了治疗升级。
核心结论
- 英国治疗升级率较高可能由疾病活动度更高和队列更年轻解释。
- 面对面银屑病关节炎咨询中高水平的协作提示共享决策方法得到有效实施。
- 数据表明在疾病活动度轻的患者中,仅感知协作较高的患者接受了治疗升级。
- 作者提出前瞻性研究应检验共享决策对银屑病关节炎患者结局的影响。
研究设计与样本
- ASSIST研究为横断面观察研究,纳入2021年7月至2022年3月期间面对面就诊的≥18岁银屑病关节炎患者。
- 共纳入来自英国、法国、德国、意大利和西班牙24个中心的503例患者。
- 记录患者人口学、当前治疗和治疗决策,以CollaboRATE问卷评估临床医生协作努力、PEPPI-5工具评估患者沟通信心。
- 试验注册号:clinicaltrials.gov,NCT05171270。
主要发现
- 医生和患者报告的病活动度指标在英国最高。
- 英国传统合成DMARDs占当前银屑病关节炎治疗比例高于欧洲大陆(66.4% vs 44.9%),生物制剂DMARDs比例则不同(36.4% vs 64.4%)。
- 实施治疗升级在英国最常见。
- CollaboRATE和PEPPI-5评分在各中心均较高。
- 31例CollaboRATE低分(<4.5)患者中,无PsAID-12低分(<5)者接受治疗升级;465例CollaboRATE≥4.5患者中,59例PsAID-12低分者接受了治疗升级。
关键数值与推荐
- CollaboRATE低分定义为<4.5,PsAID-12低分定义为<5。
- 传统合成DMARDs占当前治疗比例:英国66.4% vs 欧洲大陆44.9%。
- 生物制剂DMARDs占当前治疗比例:英国36.4% vs 欧洲大陆64.4%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Shared decision-making (SDM) is advocated to improve patient outcomes in PsA. We analysed current prescribing practices and the extent of SDM in PsA across Europe. METHODS: The ASSIST study was a cross-sectional observational study of PsA patients ≥18 years of age attending face-to-face appointments between July 2021 and March 2022. Patient demographics, current treatment and treatment decisions were recorded. SDM was measured by the clinician's effort to collaborate (CollaboRATE questionnaire) and patient communication confidence (PEPPI-5 tool). RESULTS: A total of 503 patients were included from 24 centres across the UK, France, Germany, Italy and Spain. Physician- and patient-reported measures of disease activity were highest in the UK. Conventional synthetic DMARDs constituted a higher percentage of current PsA treatment in the UK than continental Europe (66.4% vs 44.9%), which differed from biologic DMARDs (36.4% vs 64.4%). Implementing treatment escalation was most common in the UK. CollaboRATE and PEPPI-5 scores were high across centres. Of 31 patients with low CollaboRATE scores (<4.5), no patients with low PsAID-12 scores (<5) had treatment escalation. However, of 465 patients with CollaboRATE scores ≥4.5, 59 patients with low PsAID-12 scores received treatment escalation. CONCLUSIONS: Higher rates of treatment escalation seen in the UK may be explained by higher disease activity and a younger cohort. High levels of collaboration in face-to-face PsA consultations suggests effective implementation of the SDM approach. Our data indicate that in patients with mild disease activity, only those with higher perceived collaboration underwent treatment escalation. Prospective studies should examine the impact of SDM on PsA patient outcomes. TRIAL REGISTRATION: clinicaltrials.gov, NCT05171270.
引用
- Watson L, Coyle C, Whately-Smith C, et al. An international multicentre analysis of current prescribing practices and shared decision-making in psoriatic arthritis. Rheumatology (Oxford). 2024. PMID: 38011669. doi:10.1093/rheumatology/kead621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。